News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
659,235 Results
Type
Article (54029)
Company Profile (197)
Press Release (605000)
Multimedia
Podcasts (123)
Webinars (15)
Section
Business (179916)
Career Advice (2738)
Deals (33199)
Drug Delivery (130)
Drug Development (79359)
Employer Resources (167)
FDA (16749)
Job Trends (15307)
News (318053)
Policy (32563)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2856)
Accelerated approval (34)
Adcomms (35)
Allergies (146)
Alliances (46560)
ALS (173)
Alzheimer's disease (1719)
Antibody-drug conjugate (ADC) (331)
Approvals (16937)
Artificial intelligence (536)
Autoimmune disease (161)
Automation (38)
Bankruptcy (342)
Best Places to Work (11574)
BIOSECURE Act (19)
Biosimilars (203)
Biotechnology (133)
Bladder cancer (162)
Brain cancer (64)
Breast cancer (657)
Cancer (4882)
Cardiovascular disease (439)
Career advice (2328)
Career pathing (40)
CAR-T (296)
CDC (56)
Celiac Disease (2)
Cell therapy (779)
Cervical cancer (34)
Clinical research (68035)
Collaboration (1766)
Company closure (5)
Compensation (536)
Complete response letters (72)
COVID-19 (2952)
CRISPR (94)
C-suite (842)
Cystic fibrosis (149)
Data (6170)
Decentralized trials (2)
Denatured (27)
Depression (145)
Diabetes (520)
Diagnostics (6730)
Digital health (42)
Diversity (7)
Diversity, equity & inclusion (39)
Drug discovery (250)
Drug pricing (211)
Drug shortages (32)
Duchenne muscular dystrophy (236)
Earnings (70277)
Editorial (64)
Employer branding (22)
Employer resources (151)
Events (90049)
Executive appointments (991)
FDA (19878)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (1488)
Gene editing (206)
Generative AI (48)
Gene therapy (636)
GLP-1 (1095)
Government (5017)
Grass and pollen (8)
Guidances (384)
Healthcare (18790)
HIV (62)
Huntington's disease (48)
IgA nephropathy (85)
Immunology and inflammation (276)
Immuno-oncology (57)
Indications (100)
Infectious disease (3232)
Inflammatory bowel disease (190)
Inflation Reduction Act (14)
Influenza (116)
Intellectual property (243)
Interviews (513)
IPO (14838)
IRA (51)
Job creations (4044)
Job search strategy (1916)
JPM (68)
Kidney cancer (16)
Labor market (77)
Layoffs (632)
Leadership (39)
Legal (7391)
Liver cancer (98)
Longevity (15)
Lung cancer (663)
Lymphoma (375)
Machine learning (42)
Management (60)
Manufacturing (797)
MASH (166)
Medical device (13649)
Medtech (13697)
Mergers & acquisitions (19342)
Metabolic disorders (1358)
Multiple sclerosis (162)
NASH (21)
Neurodegenerative disease (347)
Neuropsychiatric disorders (94)
Neuroscience (2997)
Neurotech (1)
NextGen: Class of 2026 (6773)
Non-profit (4882)
Now hiring (55)
Obesity (660)
Opinion (303)
Ovarian cancer (164)
Pain (210)
Pancreatic cancer (223)
Parkinson's disease (294)
Partnered (33)
Patents (469)
Patient recruitment (482)
Peanut (59)
People (55959)
Pharmaceutical (32)
Pharmacy benefit managers (32)
Phase 1 (21173)
Phase 2 (29703)
Phase 3 (22738)
Pipeline (5125)
Policy (315)
Postmarket research (2564)
Preclinical (8260)
Press Release (63)
Prostate cancer (242)
Psychedelics (52)
Radiopharmaceuticals (264)
Rare diseases (884)
Real estate (5740)
Recruiting (73)
Regulatory (24691)
Reports (40)
Research institute (2575)
Resumes & cover letters (416)
Rett syndrome (28)
RNA editing (16)
RSV (83)
Schizophrenia (152)
Series A (250)
Series B (192)
Service/supplier (8)
Sickle cell disease (101)
Special edition (23)
Spinal muscular atrophy (168)
Sponsored (37)
Startups (3606)
State (1)
Stomach cancer (19)
Supply chain (108)
Tariffs (96)
The Weekly (94)
Vaccines (1117)
Venture capital (96)
Weight loss (451)
Women's health (82)
Worklife (22)
Date
Last 7 days (545)
Last 30 days (1873)
Last 365 days (28365)
2026 (2739)
2025 (28771)
2024 (33081)
2023 (37836)
2022 (48493)
2021 (52902)
2020 (52608)
2019 (46512)
2018 (35735)
2017 (32328)
2016 (31338)
2015 (35417)
2014 (27071)
2013 (22252)
2012 (23987)
2011 (24761)
2010 (22069)
Location
Africa (946)
Alabama (85)
Alaska (7)
Arizona (244)
Arkansas (14)
Asia (39317)
Australia (6769)
California (10696)
Canada (2845)
China (1073)
Colorado (461)
Connecticut (442)
Delaware (280)
Europe (90562)
Florida (1493)
Georgia (325)
Hawaii (4)
Idaho (62)
Illinois (827)
India (64)
Indiana (501)
Iowa (21)
Japan (403)
Kansas (117)
Kentucky (41)
Louisiana (25)
Maine (80)
Maryland (1275)
Massachusetts (6897)
Michigan (310)
Minnesota (564)
Mississippi (6)
Missouri (131)
Montana (29)
Nebraska (28)
Nevada (118)
New Hampshire (84)
New Jersey (2694)
New Mexico (31)
New York (2716)
North Carolina (1338)
North Dakota (10)
Northern California (5120)
Ohio (301)
Oklahoma (21)
Oregon (41)
Pennsylvania (1981)
Puerto Rico (22)
Rhode Island (44)
South America (1293)
South Carolina (62)
South Dakota (1)
Southern California (4257)
Tennessee (168)
Texas (1572)
United States (36448)
Utah (347)
Vermont (1)
Virginia (253)
Washington D.C. (78)
Washington State (860)
West Virginia (4)
Wisconsin (107)
Wyoming (2)
659,235 Results for "evolva sa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Battelle Named Key Subcontractor to SA-TECH for Mission Support Services Contract at U.S. Army Dugway Proving Ground
January 30, 2026
·
3 min read
Press Releases
POXEL SA: Update on the Proposed Recovery Plan and Organisation of a Webinar
November 24, 2025
·
19 min read
Press Releases
Moolec Science S.A. Receives Nasdaq Staff Memo Supporting Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders’ Equity Requirement
January 26, 2026
·
4 min read
Press Releases
Urteste S.A. launches European multicenter clinical study of the Panuri test
November 7, 2025
·
4 min read
Duchenne muscular dystrophy
Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up
After a series of deaths in patients taking Sarepta Therapeutics’ gene therapies, doubt has crept into investor sentiments around the long-time Wall Street darling, and patients may soon begin looking elsewhere.
February 5, 2026
·
5 min read
·
Dan Samorodnitsky
Podcast
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
Roche’s obesity candidate achieves 22.5% weight loss in Phase II; Moderna pulls the plug on late-stage vaccine trials as Health Secretary Robert F. Kennedy’s anti-vaccine policies and rhetoric continues; and embattled gene therapy maker Sarepta announces new data in Duchenne muscular dystrophy.
January 28, 2026
·
1 min read
·
Heather McKenzie
JPM
JPM26: Biopharma Projected Positivity in San Francisco. Now It’s Time To Execute
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
January 27, 2026
·
6 min read
·
Annalee Armstrong
Duchenne muscular dystrophy
Sarepta’s DMD Gene Therapy Staves Off Disease Three Years After Treatment
After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.
January 26, 2026
·
2 min read
·
Dan Samorodnitsky
Press Releases
Urteste S.A. Completes Development of Panuri Test – Company Plans to Launch Clinical Study in Q3 2025
July 22, 2025
·
4 min read
RNA editing
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop partnerships, pitch the potential of its new AATD program and find more money to keep the dream alive.
January 16, 2026
·
3 min read
·
Dan Samorodnitsky
1 of 65,924
Next
